Chinese chip stocks jump as Beijing reportedly warns against Nvidia’s H20
Amy L. Burroughs, Chief Executive Officer of Terns Pharmaceuticals , Inc. (NASDAQ:TERN), recently purchased 23,314 shares of the company’s common stock at a price of $3.8702 per share. The transaction, which occurred on June 25, 2025, amounted to a total investment of $90,229.
Following this transaction, Burroughs directly owns 47,083 shares of Terns Pharmaceuticals, Inc. In other recent news, Terns Pharmaceuticals has completed enrollment for its Phase 2 FALCON clinical trial of TERN-601, an oral GLP-1 receptor agonist for obesity. The company anticipates releasing topline data in the fourth quarter of 2025. Meanwhile, Terns Pharmaceuticals continues to advance its TERN-701 treatment, having enrolled the first patient in a dose expansion trial, which includes higher doses of 320mg and 500mg administered once daily. This development is part of the company’s CARDINAL study. Analyst firms have also made notable adjustments to their outlook on Terns Pharmaceuticals. BMO Capital Markets reduced its price target from $26 to $15 while maintaining an Outperform rating, citing macroeconomic factors and recent clinical developments. Citizens JMP and JMP Securities both reiterated a Market Outperform rating with a $20 price target, highlighting positive efficacy data for TERN-701 and developments in the GLP-1 receptor agonist space. Mizuho (NYSE:MFG) Securities maintained an Outperform rating with a $14 price target, emphasizing the competitive advantage gained from Pfizer (NYSE:PFE)’s discontinuation of its GLP-1 agonist, danuglipron. These developments have generated increased interest in Terns Pharmaceuticals’ obesity treatment portfolio, with expectations of strategic partnerships potentially emerging. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.